Weihong Xu

National Cancer Institute — United States

Medicine · Health Sciences

35h-index19.9kcitations86works13.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(22), Chronic Lymphocytic Leukemia Research(11), Immune Cell Function and Interaction(9), Cancer-related molecular mechanisms research(8), RNA modifications and cancer(8)

Publications86 total

45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)
Hematological Oncology·2025· 2 citedOpen Access
316 | MULTI‐TARGETED THERAPY WITH VIPOR‐P IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE
Hematological Oncology·2025Open Access
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
Blood·2024· 1 citedOpen Access
Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
Blood·2024· 1 cited
Global prevalence and disability-adjusted life years of hypertensive heart disease: A trend analysis from the Global Burden of Disease Study 2019
Journal of Global Health·2024· 19 citedOpen Access
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
New England Journal of Medicine·2024· 59 citedOpen Access
Abstract 3913: Molecular mechanism of action and targets of glucocorticoids in lymphoma therapy
Cancer Research·2024
Response to Bruton’s tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy
Cancer Cell·2024· 22 citedOpen Access
Molecular Mechanism of Action of Glucocorticoids in Lymphoma Therapy
Blood·2023· 2 cited
Exceptional Response to BTK Inhibitors in Aggressive Lymphomas Linked to Chronic Selective Autophagy
Blood·2023· 1 citedOpen Access
Phase Ib/II Study of Multi-Targeted Therapy with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Blood·2023· 5 cited
Nursing of a patient with periarthritis of the shoulder treated by Traditional Chinese Medicine ointment rubbing combined with Traditional Chinese Medicine hot pack therapy
Chinese Journal of Integrative Nursing·2022Open Access
Yb/Er: Cs2Ag(In/Bi)Cl6 lead-free double perovskite for dual-modal optical temperature sensing
Journal of Luminescence·2022· 32 cited
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Blood Cancer Discovery·2021· 57 citedOpen Access
Extensive germline genome engineering in pigs
Nature Biomedical Engineering·2020· 158 cited
Extensive Mammalian Germline Genome Engineering
2019· 12 citedOpen Access
Community members in activated sludge as determined by molecular probe technology
Water Research·2019· 4 citedOpen Access
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma
Cancer Cell·2018· 120 citedOpen Access
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
Nature·2018· 397 citedOpen Access
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
New England Journal of Medicine·2018· 2.2k citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Louis M. Staudt(19), George W. Wright(16), Hong Zhao(16), Yandan Yang(14), Wenzhong Xiao(13), Elaine S. Jaffe(12), Ronald W. Davis(11), Arthur L. Shaffer(11), Wenming Xiao(11), Wing C. Chan(11), Randy D. Gascoyne(11), Elı́as Campo(11), Andreas Rosenwald(11), German Ott(11), Jan Delabie(11), Lisa M. Rimsza(11), Ryan M. Young(10), Michele Ceribelli(9), Xin Yu(8), Wyndham H. Wilson(8)